BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 30009716)

  • 1. Overexpression of Hepassocin in Diabetic Patients with Nonalcoholic Fatty Liver Disease May Facilitate Increased Hepatic Lipid Accumulation.
    Abdelmoemen G; Khodeir SA; Zaki AN; Kassab M; Abou-Saif S; Abd-Elsalam S
    Endocr Metab Immune Disord Drug Targets; 2019; 19(2):185-188. PubMed ID: 30009716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of hepassocin in the development of non-alcoholic fatty liver disease.
    Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
    J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
    Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
    EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease.
    Lin Y; Ding D; Huang Q; Liu Q; Lu H; Lu Y; Chi Y; Sun X; Ye G; Zhu H; Wei J; Dong S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):869-882. PubMed ID: 28483554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-17 family-mediated regulation of Pknox1 influences hepatic steatosis and insulin signaling.
    Ye D; Lou G; Zhang T; Dong F; Liu Y
    J Cell Mol Med; 2018 Dec; 22(12):6167-6175. PubMed ID: 30338914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis.
    Kim JY; Park KJ; Hwang JY; Kim GH; Lee D; Lee YJ; Song EH; Yoo MG; Kim BJ; Suh YH; Roh GS; Gao B; Kim W; Kim WH
    J Hepatol; 2017 Aug; 67(2):349-359. PubMed ID: 28365312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of metabolic risk factors for developing nonalcoholic fatty liver in patients with type 2 diabetes mellitus].
    Guo M; Xi G; Yang N; Yao H
    Zhonghua Gan Zang Bing Za Zhi; 2014 Aug; 22(8):631-5. PubMed ID: 25243967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effects of globular adiponectin in diabetic rats with nonalcoholic fatty liver disease.
    Ma H; Cui F; Dong JJ; You GP; Yang XJ; Lu HD; Huang YL
    World J Gastroenterol; 2014 Oct; 20(40):14950-7. PubMed ID: 25356056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactin improves hepatic steatosis via CD36 pathway.
    Zhang P; Ge Z; Wang H; Feng W; Sun X; Chu X; Jiang C; Wang Y; Zhu D; Bi Y
    J Hepatol; 2018 Jun; 68(6):1247-1255. PubMed ID: 29452209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease.
    Wasilewska N; Bobrus-Chociej A; Harasim-Symbor E; Tarasów E; Wojtkowska M; Chabowski A; Lebensztejn DM
    Lipids Health Dis; 2018 Sep; 17(1):216. PubMed ID: 30208901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator.
    Zhuge B; Li G
    Biochem Biophys Res Commun; 2017 Dec; 494(3-4):687-692. PubMed ID: 29107687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.
    Marchesini G; Brizi M; Bianchi G; Tomassetti S; Bugianesi E; Lenzi M; McCullough AJ; Natale S; Forlani G; Melchionda N
    Diabetes; 2001 Aug; 50(8):1844-50. PubMed ID: 11473047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatty liver as a consequence and cause of insulin resistance: lessons from type 2 diabetic liver.
    Takamura T; Misu H; Ota T; Kaneko S
    Endocr J; 2012; 59(9):745-63. PubMed ID: 22893453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [ANTHROPOMETRIC CHARACTERISTICS AND PARAMETERS OF LIPID-CARBOHYDRATE METABOLISM IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE AND HYPERTENSION DEPENDING ON THE DEGREE OF HEPATIC STEATOSIS].
    Babak О; Bashkirova А
    Georgian Med News; 2018 Nov; (284):59-65. PubMed ID: 30618391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Patatin-Like Phospholipase Domain-Containing 3 Gene for Hepatic Lipid Content and Insulin Resistance in Diabetes.
    Zaharia OP; Strassburger K; Knebel B; Kupriyanova Y; Karusheva Y; Wolkersdorfer M; Bódis K; Markgraf DF; Burkart V; Hwang JH; Kotzka J; Al-Hasani H; Szendroedi J; Roden M;
    Diabetes Care; 2020 Sep; 43(9):2161-2168. PubMed ID: 32910776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of APN and TNF-α in type 2 diabetes mellitus complicated by nonalcoholic fatty liver disease.
    Lin X; Zhang Z; Chen JM; Xu YY; Ye HR; Cui J; Fang Y; Jin Y; Zhu DR; Yuan L
    Genet Mol Res; 2015 Apr; 14(2):2940-6. PubMed ID: 25966055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased Hepatic PDGF-AA Signaling Mediates Liver Insulin Resistance in Obesity-Associated Type 2 Diabetes.
    Abderrahmani A; Yengo L; Caiazzo R; Canouil M; Cauchi S; Raverdy V; Plaisance V; Pawlowski V; Lobbens S; Maillet J; Rolland L; Boutry R; Queniat G; Kwapich M; Tenenbaum M; Bricambert J; Saussenthaler S; Anthony E; Jha P; Derop J; Sand O; Rabearivelo I; Leloire A; Pigeyre M; Daujat-Chavanieu M; Gerbal-Chaloin S; Dayeh T; Lassailly G; Mathurin P; Staels B; Auwerx J; Schürmann A; Postic C; Schafmayer C; Hampe J; Bonnefond A; Pattou F; Froguel P
    Diabetes; 2018 Jul; 67(7):1310-1321. PubMed ID: 29728363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
    Asrih M; Jornayvaz FR
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis.
    Dongiovanni P; Romeo S; Valenti L
    Biomed Res Int; 2015; 2015():460190. PubMed ID: 26273621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating level of CTRP1 in patients with nonalcoholic fatty liver disease (NAFLD): is it through insulin resistance?
    Shabani P; Naeimi Khaledi H; Beigy M; Emamgholipour S; Parvaz E; Poustchi H; Doosti M
    PLoS One; 2015; 10(3):e0118650. PubMed ID: 25767880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.